NIH-funded research Sbir 2 grant

A blood filter that works without anticoagulants for kidney treatment

Official title: A silicon nanopore membrane blood filter enabling anticoagulant free continuous renal replacement therapy for acute kidney injury

Funded at Silicon Kidney, LLC · NIH-10784679 · Data updated 2026-11-12

This study is testing a new blood filter called the HemoCartridge that could help patients with acute kidney injury by cleaning their blood without needing blood-thinning medications, making treatment easier and safer.

More Acute Kidney Injury research and trials

Quick facts

Grant typeSbir 2 grant
Study typeNIH-funded research
Funding institutionSilicon Kidney, LLC
NIH-funded
Lab location1 site (San Ramon, United States)
Project startSeptember 19, 2019
Project endJanuary 31, 2026
Funding year2024
Award (this year)$1,019,958
NIH project number5R44DK120242-03
Project IDNIH-10784679 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are critically ill patients suffering from acute kidney injury who require continuous renal replacement therapy.

Less likely to help

Patients with stable kidney function or those not requiring renal replacement therapy may not benefit from this research.

What this research studies

This research focuses on developing a new type of blood filter called the HemoCartridge, which uses advanced silicon nanopore membrane technology to treat patients with acute kidney injury (AKI) without the need for anticoagulant medications. By eliminating the use of anticoagulants, the HemoCartridge aims to simplify the treatment process, reduce complications, and lower costs associated with continuous renal replacement therapy (CRRT). The research involves creating a clinical-scale version of this filter and testing its effectiveness in clearing toxins from the blood while ensuring compatibility with blood components. This innovative approach could significantly improve the care of critically ill patients requiring kidney support.

Why it matters

Potential benefit: If successful, this research could provide a safer and more cost-effective treatment option for patients with acute kidney injury.

How similar studies have gone: While the approach of using a silicon nanopore membrane for blood filtration is innovative, similar technologies have shown promise in other applications, indicating potential for success.

Where this research is happening

  • Silicon Kidney, LLC
    San Ramon, United States
    Active

Researchers

  • Principal investigator: Blaha, Charles — Silicon Kidney, LLC
  • Study coordinator: Blaha, Charles

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.